CARDIONOVUM GmbH, a medical technology company developing and commercializing innovative medical devices such as drug-coated balloons and drug-eluting stents for the treatment of coronary and peripheral artery disease, announced today the enrollment of the first patient in the MAGNIFICENT trial.
Cardionovum experiences increase in demand for its innovative, and next generation „RESTORE Paclitaxel-releasing coronary balloon dilatation catheter.“ The American Journal of Cardiology, issue December 2015, published study results on the efficacy and safety of Paclitaxel coated balloon catheters for the treatment of in-stent restenosis in high risk patients. The RESTORE DEB showed significant superiority with lowest incidence of restenosis, if compared to other contemporary coronary DEBs.
Cardionovum prepares for a first international publication on 6-12 months FU patient results from the ongoing APERTO clinical study program. The APERTO Paclitaxel-releasing high pressure shunt balloon dilatation catheter was exclusively designed to treat shunt stenosis of hemodialysis patients.
Cardionovum invites you to participate in on demand interviwes:
XLIMIT Trial RCT, with Dr. Luca Testa from Italy. Goal: to assess angiographic and clinical performance of the Xlimus Biodegradable Polymer Sirolumus-eluting stent versus a gold standard like Synergy Biodegradable Polymer Everolimus Stent in patients treated with percutaneous coronary angioplasty.
Hyper Registry with Dr. Alfonso Ileasi from Italy. Goal: Asses the clinical results after a Hybrid Approach in diffuse CAD lesions longer tan 28mm combinig Restore DCB and New generation DES.